甲磺酸培高利特可能改善帕金森病患者的疲劳症状。
Pergolide mesilate may improve fatigue in patients with Parkinson's disease.
作者信息
Abe K, Takanashi M, Yanagihara T, Sakoda S
机构信息
Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
出版信息
Behav Neurol. 2001;13(3-4):117-21. doi: 10.1155/2002/473140.
OBJECTIVES
Fatigue is a complaint frequently encountered among patients with Parkinson's disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD.
METHODS
We evaluated 41 patients with PD and controls. We assessed the degree of fatigue by using a fatigue scale. The severity of PD was evaluated by the Hoehn and Yahr Scale and the unified Parkinson's disease rating scale (UPDRS).
RESULTS
After five weeks from prescription, patients taking pergolide mesilate showed significant improvement in the fatigue scale (from 5.1 +/- 0.7 to 4.4 +/- 0.55, p < 0.05, ) but patients taking bromocriptine did not (from 4.8 +/- 0.9 to 4.7 +/- 0.8).
CONCLUSIONS
Our study suggested the possibility of functional correlation between fatigue and D1 receptor in patients with PD.
目的
疲劳是帕金森病（PD）患者中经常遇到的主诉。考虑到疲劳与多巴胺能功能障碍之间的可能关系，我们研究了甲磺酸培高利特（一种D2和D1多巴胺受体激动剂）和溴隐亭（一种D2选择性多巴胺受体）对PD患者的影响。
方法
我们评估了41例PD患者和对照组。我们使用疲劳量表评估疲劳程度。通过Hoehn和Yahr量表以及统一帕金森病评定量表（UPDRS）评估PD的严重程度。
结果
在开药五周后，服用甲磺酸培高利特的患者在疲劳量表上有显著改善（从5.1±0.7降至4.4±0.55，p<0.05），但服用溴隐亭的患者没有（从4.8±0.9降至4.7±0.8）。
结论
我们的研究提示了PD患者疲劳与D1受体之间功能关联的可能性。
Zotero 插件